Respiratory syncytial virus vaccination in systemic autoimmune rheumatic diseases: a systematic review
Authors' conclusion
RSV poses a relevant, though incompletely quantified, risk for SARD patients. Vaccination appears effective and safe in immunocompromised populations, but protection may wane more rapidly.
Study context
- Population
- Adults with systemic autoimmune rheumatic diseases (SARDs), including those receiving immunosuppressive therapies49 studies
- Outcome
- RSV epidemiology, vaccine effectiveness, immunogenicity and safety in SARDs
Methodological detailsobservational studies, clinical trials and pharmacovigilance reports included, databases searched from inception to 28th January 2026, 249 unique records returned, 43 met inclusion criteria; 6 studies from supplementary search
- Observational studies, clinical trials and pharmacovigilance reports included
- Databases searched from inception to 28th January 2026
- 249 unique records returned, 43 met inclusion criteria; 6 studies from supplementary search
Pooled result
As reported in the abstract
Only one study reported respiratory syncytial virus (RSV) outcomes in SARD patients
1
First-season RSV vaccine effectiveness in immunocompromised adults
60-73%
Safety
- No consistent autoimmune safety signals identified; data in SARD populations limited
Original publication
Respiratory syncytial virus vaccination in systemic autoimmune rheumatic diseases: a systematic review. Rheumatology (Oxford). Published 17 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →